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Abstract 
Background: The aim of newborn screening (NBS) for CF is to detect children with ‘classic’ CF where early treatment is possible and improves 
prognosis. Children with inconclusive CF diagnosis (CFSPID) should not be detected, as there is no evidence for improvement through early 
treatment. No algorithm in current NBS guidelines explains what to do when sweat test (ST) fails. This study compares the performance of three 
different algorithms for further diagnostic evaluations when ﬁrst ST is unsuccessful, regarding the numbers of children detected with CF and 
CFSPID, and the time until a deﬁnite diagnosis. 
Methods: In Switzerland, CF-NBS was introduced in January 2011 using an IRT-DNA-IRT algorithm followed by a ST. In children, in whom ST 
was not possible (no or insufﬁcient sweat), 3 different protocols were applied between 2011 and 2014: in 2011, ST was repeated until it was 
successful (protocol A), in 2012 we proceeded directly to diagnostic DNA testing (protocol B), and 2013–2014, fecal elastase (FE) was measured 
in the stool, in order to determine a pancreas insufﬁciency needing immediate treatment (protocol C). 
Results: The ratio CF:CFSPID was 7:1 (27/4) with protocol A, 2:1 (22/10) with protocol B, and 14:1 (54/4) with protocol C. The mean time to 
deﬁnite diagnosis was signiﬁcantly shorter with protocol C (33 days) compared to protocol A or B (42 and 40 days; p = 0.014 compared to A, and 
p = 0.036 compared to B). 
Conclusions: The algorithm for the diagnostic part of the newborn screening used in the CF centers is important and affects the performance of a 
CF-NBS program with regard to the ratio CF:CFSPID and the time until deﬁnite diagnosis. Our results suggest to include FE after initial sweat test 
failure in the CF-NBS guidelines to keep the proportion of CFSPID low and the time until deﬁnite diagnosis short. 
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1. Introduction 
 
Many countries have introduced national programs for newborn screening (NBS) for cystic fibrosis (CF) using a large 
variety of protocols [1,2]. In accordance with the WHO screening guidelines [3], the main aim of CF-NBS is to detect children 
with ‘classic’ CF [4] where early treatment is possible and improves prognosis. Children with equivocal CF diagnosis, now 
called CF screen positive inconclusive diagnosis (CFSPID) [5,6], should not be detected, as their prognosis is favorable and 
there is no evidence for improvement through early treatment. In this specific group, the harms of early detection with 
unnecessary medicalization and burden to the family outweigh potential benefits [7]. 
Sweat testing remains the gold standard in the diagnosis of CF [1,8]. However, sweat collection in infants is challenging 
with a failure rate of up to 40% below 3 months of age [9–13]. No algorithm in current NBS guidelines explains what to do 
when sweat tests fail. In Switzerland, CF-NBS was introduced in January 2011 using an IRT-DNA-IRT algorithm followed by a 
sweat test [14]. Initially, we repeated the sweat test after a few weeks or months until it was successful. This led to a long 
waiting time for definite diagnosis, and anxiety among families. After 1 year, we changed the algorithm and directly performed 
genetic testing after a sweat test failure. This led to more CFSPID and no reduction of the waiting time. We therefore changed 
the algorithm again and introduced the measurement of fecal elastase (FE) to reduce the number of CFSPID. 
This study compares the performance of these three different algorithms for further diagnostic evaluations when first sweat 
test is unsuccessful. We compared: 1) the numbers of children detected with CF and CFSPID; and 2) the time until a definite 
diagnosis. 
 
2. Methods 
 
The CF-NBS in Switzerland has been described in detail elsewhere [15,16]. In short, the screening procedure in the 
laboratory (screening part) comprises the measurement of IRT in a heel prick test (Guthrie card) on day 4. If IRT is above the 
cut-off (99.2 percentile), a screening for the most common CFTR mutations is performed. The genetic kit included the seven 
most common CF mutations in Switzerland. Since 2013 the kit included 18 mutations (the 7 common ones, plus 11 rare 
mutations), because the components of the initial in-house kit were no longer available and a commercial kit was used. If no 
mutation is found, a second IRT is performed if the first IRT was ≥ 60 ng/ml. All children with a positive screening result are 
then referred to the nearest CF center for diagnostic evaluations (diagnostic part). Due to the law on human genetics, the 
screening laboratory is not allowed to report details of CFTR mutations, as the Swiss NBS program requires only an oral 
informed consent (with a possibility for parents to refuse) but not a written consent. The CF centers are only informed that 
none, one or two mutations were found, but not which mutations these are. All centers perform sweat tests (using 
Macroduct® sweat collection system) according to the current best practice guidelines [8,17–19]. If a sweat test is positive 
(chloride ≥ 60 mmol/l) or borderline (chloride 30–59 mmol/l)  a  diagnostic  DNA  analysis  is  performed.  A CF diagnosis is 
based on two positive sweat tests or two CF-causing CFTR mutations (www.cftr2.org) [8]. A CFSPID diagnosis, according to 
the ECFS consensus, is based on a normal sweat chloride value (b 30 mmol l) and two CFTR mutations, one of which has 
unclear phenotypic consequence or intermediate sweat chloride values (30–59 mmol/l) and one or no CFTR mutations [5]. 
In children, in whom sweat tests did not give a reliable result (no sweat, or less than 15 μl), 3 different protocols were 
applied between 2011 and 2014: 
 
- Protocol A (initial protocol; 2011): We repeated the sweat test after a few weeks or months until it was successful. 
- Protocol B (2012): We proceeded directly to diagnostic DNA testing. 
- Protocol C (2013–2014): We proceeded to measure FE in the stool, in order to determine a pancreas insufficiency (PI) 
needing immediate treatment. If FE was low (b 200 μg/g) suggesting PI, we proceeded to a diagnostic DNA testing and 
started pancreatic enzyme replacement therapy (PERT). If FE was normal, we waited and repeated the sweat test when the 
child weighted ≥ 4000 g (Fig. 1). 
 
To evaluate these 3 protocols, we compared the following parameters over all 3 protocols and between each protocol 
separately (A vs. B; A vs. C; and B vs. C). First, we compared the proportion of final diagnoses (CF, CFSPID, no CF) 
between protocols, using chi-square tests. Second, we calculated the proportion and 95% confidence interval (CI) of 
CFSPID among all positive diagnoses (CF + CFSPID) for each protocol and compared them between protocols. Third, we 
calculated the mean time to definite (genetically confirmed) diagnosis by protocol and compared them using t-tests. Finally, we 
described the proportion and 95% CI of children with N 2 months waiting time until definite diagnosis by protocol, and 
compared them using chi-square statistics. 
 
 
 
 
 
3. Results 
 
From January 2011 until December 2014, 339,685 children were screened for CF in Switzerland. Of these, 368 newborns were 
referred to a pediatric CF center for further investigations, 87 during protocol A (2011), 85 during protocol B (2012) and 193 
during protocol C (2013/2014). The change of the DNA screening kit in 2013 (18 instead of 7 CFTR mutations) led to 4 
additional referrals, of whom two were then diagnosed with CF, and two were healthy carriers, none had CFSPID. Overall, 103 
children were diagnosed with CF, 18 with CFSPID and 244 children were CF negative (3 children were without follow-up of 
whom 2 had died). The final diagnoses differed significantly between the 3 protocols (p = 0.015). When making pair-wise 
comparisons, only the difference between B and C was statistically significant (Table 1). 
 
 
 
 
Fig. 1. Diagnostic procedures in the CF centers in Switzerland in place since January 2013 (protocol C). Abbreviations: CFTR, cystic fibrosis transmembrane 
conductance regulator; CFSPID, CF screen positive inconclusive diagnosis; Cl, chloride; GP, general practitioner; IRT, immunoreactive trypsinogen; NBS, newborn 
screening. 
 
 
The ratio CF:CFSPID was 7:1 (27/4) with protocol A, 2:1 (22/ 
10) with protocol B, and 14:1 (54/4) with protocol C. The proportion of CFSPID among all positive diagnoses (CF 
+ CFSPID) increased from protocol A (13%; 95% CI 5– 31%) to protocol B (31%; CI 17–50%) and decreased again with protocol 
C (7%; CI –17%; Fig. 2). The mean time to definite diagnosis was significantly shorter with the third protocol. It was 42 days (range 
13–208) for protocol A, 40 days (range 14–104) for  protocol  B  (p = 0.580)  and  33 days  (range  10–152)  for protocol C (p = 
0.014 compared to A, and p = 0.036 compared to B). The proportion of families with N 2 months waiting time until diagnosis 
followed the same pattern with 17%, 15% and 7% during protocol A, B and C, respectively (Fig. 2). The median age of the children at 
unsuccessful sweat test was 22, 22, and 19 days in protocol A, B, and C respectively. 
 
4. Discussion 
 
In the Swiss Newborn Screening for CF, the introduction of genetic tests directly after sweat test failure did not reduce the 
time to diagnosis, but increased the proportion of CFSPID among all positive diagnoses. The introduction of FE reduced 
both time to diagnosis and proportion of CFSPID, although the latter was not statistically significant because of low numbers. A 
normal FE (N 200 μg/g) in the first year of life does not exclude CF as FE can fluctuate in the first year [20]. Therefore 
repeated sweat chloride test is mandatory for all children with normal FE, as reflected in our most recent algorithm (Fig. 1). We 
are aware that FE results are not everywhere available within a few days, as many laboratories perform the test only once  
a  week.  Overall, the  Swiss  CF-NBS  had  a good 
 
 
 
 
 
 Table 1 
Referrals and final diagnoses in the Swiss NBS for the 3 different protocols. 
Protocol A 
2011 
Protocol B 
2012 
Protocol C 
2013/2014 
 
3 protocols, 
p-value a 
 
A vs. B, 
p-value b 
 
A vs. C, 
p-value b 
 
B vs. C, 
p-value b 
N % N % N % 
CF 27 31.0 22 25.9 54 28.0 
CFSPID 4 4.6 10 11.8 4 2.1 0.015 0.208 0.405 0.003 
No CF 56 64.4 53 62.4 135 70.0 
Total referrals 87 100 85 100 193 c 100 
Abbreviations: CF, cystic fibrosis; CFSPID, CF screen positive inconclusive diagnosis; N, number. 
a p-value calculated from chi-square statistics comparing all 3 protocols. 
b p-value calculated from chi-square statistics comparing protocol A with B, A with C and B with C, respectively. 
c Three children without follow-up in this protocol period. 
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Fig. 2. Proportion of CFSPID among all positive diagnoses (CF + CFSPID) and families with N 2 months waiting time until definite diagnosis, by type of protocol. 
The figure shows the proportion and 95% confidence interval of CFSPID among all positive diagnoses (CF + CFSPID) and of families with more than 2 months 
waiting time until definite (genetically confirmed) diagnosis, stratified by screening protocol. Abbreviations: CFSPID, CF screen positive inconclusive diagnosis; CI, 
confidence interval. 
 
performance when comparing with ECFS standards of care best practice guidelines [2]. 
 
The major limitations of our study are the small sample size and short duration of our observation period. The latter two explain 
why not all differences were statistically significant. The change of the number of screened CFTR mutations in 2013 did not affect 
the results much: it led to four referrals, of which two were diagnosed with CF, but none as CFSPID. Their initial IRT-1 was very 
high (124 and 89, respectively), so they would probably have been detected via the safety loop. But if not, the ratio CF:CFSPID 
would only have changed from 13.5 (54/4) to 13,0 (52/4), which is not significant. Since it started, the Swiss NBS program aimed 
to avoid detecting children with CFSPID, as it is unclear how these should be monitored and treated. A diagnosis of CFSPID leads 
often to unnecessary medicalization and anxiety among parents, and exposes the children to infections in CF clinics when 
they are followed [7]. The ratio CF:CFSPID of the final protocol (14:1) was in the aimed range (N 10:1), while the first two 
protocols (7:1 and 2:1 respectively) were not. Neither were the ratios, reported from Canada or Italy (1.4:1–2.9:1) [6]. 
In summary, this study shows that the algorithm for the diagnostic part of the newborn screening used in the CF centers is 
important and affects the performance of a CF-NBS program with regard to the ratio CF:CFSPID and the time until definite 
diagnosis. Our results suggest to include FE after initial sweat test failure in the CF-NBS guidelines to keep the proportion of 
CFSPID low and the time until definite diagnosis short. 
p=0.016 
 
p=0.770 p=0.045 
p=0.345 
 
p=0.080 p=0.002 
12.9 16.7 31.3 15 6.9 7.1 
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